2. PAHO, WHO. Epidemiological alert: Complications and sequelae of COVID-19. 12 Aug 2020. URL: https://www.paho.org/en/documents/epidemiological-alert-complications-and-sequelae-covid-19-12-august-2020 (date of access – 11.01.2022).

3. Wellcome Open Research. Perego E., Callard F., Stras L. et al. Why the patient-made term «Long Covid» is needed. 24 September 2020. URL: https://wellcomeopenresearch.org/articles/5-224 (date of access – 11.01.2022).

4. Editorial. Facing up to long COVID. Lancet. 2020; 396(10266): 1861. https://dx.doi.org/10.1016/S0140-6736(20)32662-3.

5. National Institute for Health and Care Excellence, Royal College of General Practitioners, Healthcare Improvement Scotland SIGN. COVID-19 rapid guideline: Managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence, 2020. URL: www.nice.org.uk/guidance/ng188 (date of access – 11.01.2022).

6. Barber C. The problem of «long haul» COVID. Scientific American. 29 December 2020. URL: https://www.scientificamerican.com/article/the-problem-of-long-haul-covid (date of access – 11.01.2022).

7. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. URL: https://apps.who.int/iris/handle/10665/345824 (date of access – 11.01.2022).

8. Medscape. Wilson F.P. Is Long COVID Even Real? Nov 09, 2021. URL: https://www.medscape.com/viewarticle/962479 (date of access – 11.01.2022).

9. Medscape. Long COVID more common than «Long flu», study suggests. Sep 29; 2021. URL: https://www.medscape.com/viewarticle/959942 (date of access – 11.01.2022).

10. Molteni E., Sudre C.H., Canas L.S. et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021; 5(10): 708–18. https://dx.doi.org/10.1016/S2352-4642(21)00198-X.

11. Davis H.E., Assaf G.S., McCorkell L. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38: 101019. https://dx.doi.org/10.1016/j.eclinm.2021.101019.

12. Becker J. H., Lin J. J., Doernberg M. et al. Assessment of cognitive function in patients after COVID-19 infection. AMA Network Open. 2021; 4(10): e2130645. https://dx.doi.org/10.1001/jamanetworkopen.2021.30645.

13. Helms J., Kremer S., Merdji H. et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020; 382 (23): 2268–70. https://dx.doi.org/10.1056/NEJMc2008597.

14. Pandharipande P.P., Girard T.D., Jackson J.C. et al. BRAIN-ICU Study Investigators. Long-term cognitive impairment after critical illness. N Engl J Med. 2013; 369(14): 1306–16. https://dx.doi.org/10.1056/NEJMoa130137.

15. Beraki S., Aronsson F., Karlsson H. et al. Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice. Mol Psychiatry. 2005; 10(3): 299–308. https://dx.doi.org/10.1038/sj.mp.4001545.

16. Huang L., Yao Q., Gu X. et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021; 398(10302): 747–58. https://dx.doi.org/10.1016/S0140-6736(21)01755-4.

17. Thompson E.J., Williams D.M., Alex W.J. et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv. 2021. https://dx.doi.org/10.1101/2021.06.24.21259277. Preprint.

18. Katsoularis I., Fonseca-Rodriguez O., Farrington P. et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021; 398(10300): 599–607. https://dx.doi.org/10.1016/S0140-6736(21)00896-5.

19. Thakkar S., Arora S., Kumar A. et al. A systematic review of the cardiovascular manifestations and outcomes in the setting of coronavirus-19 disease. Clin Med Insights Cardiol. 2020; 14: 1179546820977196. https://dx.doi.org/10.1177/1179546820977196.

20. Nersesjan V., Amiri M., Lebech A.M. et al. Central and peripheral nervous system complications of COVID 19: A prospective tertiary center cohort with 3 month follow up. Journal of Neurology. 2021; 268(9): 3086–104. https://dx.doi.org/10.1007/s00415-020-10380-x.

21. Garg S., Garg M., Prabhakar N., Malh А. et al. Unraveling the mystery of Covid-19 cytokine storm: from skin to organ systems. Dermatol Ther. 2020; 33(6): 1385–89. https://dx.doi.org/10.1111/dth.13859.

22. Aragao M., Leal M., Cartaxo Filho O. et al. Anosmia in COVID-19 associated with injury to the olfactory bulbs evident on MRI. AJNR Am J Neuroradiol. 2020; 41(9): 1703–6. https://dx.doi.org/10.3174/ajnr.A6675.

23. Strauss S., Lantos J., Heier L. et al. Olfactory bulb signal abnormality in patients with COVID-19 who present with neurologic symptoms. AJNR Am J Neuroradiol. 2020; 41(10): 1882–87. https://dx.doi.org/10.3174/ajnr.A6751.

24. Cosentino G., Todisco M., Hota N. et al. Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: A critical systematic review. Eur J Neurol. 2021; 28(11): 3856–65. https://dx.doi.org/10.1111/ene.15045.

25. Ye G., Pan Z., Pan Y. et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect. 2020; 80(5): 14–17. https://dx.doi.org/10.1016/j.jinf.2020.03.001.

26. Lopez Castro J. Post-COVID-19 syndrome (PC19S): Chronic reactive endotheliitis and disseminated vascular disease. Acta Med Port. 2020; 33(12): 859. https://dx.doi.org/10.20344/amp.14612.

27. Sollini M., Ciccarelli M., Cecconi M. et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an

28. Hosp J.A., Dressing A., Blazhenets G. et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021; 144(4): 1263–76. https://dx.doi.org/10.1093/brain/awab009.

29. Afrin L., Weinstock L., Molderings G. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020; 100: 327–32. https://dx.doi.org/10.1016/j.ijid.2020.09.016.

30. Troubat R., Barone P., Leman S. et al. Neuroinflammation and depression: A review. Eur J Neurosci. 2021; 53(1): 151–71. https://dx.doi.org/10.1111/ejn.14720.

31. Verdu E.F., Bercik P., Verma-Gandhu M. et al. Probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut. 2006; 55(2): 182–90. https://dx.doi.org/10.1136/gut.2005.066100

32. Frohlich E.E., Farzi A., Mayerhofer R. et al. Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication. Brain Behav Immun. 2016; 56: 140–55. https://dx.doi.org/10.1016/j.bbi.2016.02.020.

33. Hoban A.E., Stilling R.M., Ryan F.J. et al. Regulation of prefrontal cortex myelination by the microbiota. Transl Psychiatry. 2016; 6: e774. https://dx.doi.org/10.1038/tp.2016.42.

34. Leclercq S., Mian F.M., Stanisz A.M. et al. Low-dose penicillin in early life induces long-term changes in murine gut microbiota, brain cytokines and behavior. Nat Commun. 2017; 8: 15062. https://dx.doi.org/10.1038/ncomms15062.

35. Erny D., Lena A., De Angelis H. et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nature Neurosci. 2015; 18(7): 965–77. https://dx.doi.org/10.1038/nn.4030.

36. George P.M., Barratt S.L., Condliffe R. et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020; 75 (11): 1009–16. https://dx.doi.org/10.1136/thoraxjnl-2020-215314.

37. Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of covid-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021; 372: n136. https://dx.doi.org/10.1136/bmj.n136.

38. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 13.1 (09.11.2021). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/392/original/%D0%92%D0%9C%D0%A0-13.1-from-17-11-2021.pdf (дата обращения – 11.01.2022). [Interim guidelines «Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)». Version 13.1 (09.11.2021). Ministry of Healthcare of Russia. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/392/original/%D0%92%D0%9C%D0%A0-13.1-from-17-11-2021.pdf (date of access – 11.01.2022).

39. Grigoletto I., Cavalheri V., Lima F.F., Ramos E.M.C. Recovery after COVID-19: The potential role of pulmonary rehabilitation. Braz J Phys Ther. 2020; 24(6): 463–64. https://dx.doi.org/10.1016/j.bjpt.2020.07.002.

40. Candan S.A., Elibol N., Abdullahi A. Consideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19. Physiother Theory Pract. 2020; 36(6): 663–68. https://dx.doi.org/10.1080/09593985.2020.1766181.

41. Halpin S.J., McIvor C., Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021; 93(2): 1013–22. https://dx.doi.org/10.1002/jmv.26368.

42. Poyraz B.C., Poyraz C.A, Olgun Y. et al. Psychiatric morbidity and protracted symptoms after COVID-19. Psychiatry Res. 2021; 295: 113604. https://dx.doi.org/10.1016/j.psychres.2020.113604.

43. Lu Y., Li X., Geng D. et al. Cerebral micro-structural changes in COVID-19 patients – an MRI-based 3-month follow-up study. EClinicalMedicine. 2020; 25: 100484. https://dx.doi.org/10.1016/j.eclinm.2020.100484.

44. Камчатнов П.Р., Соловьева Э.Ю., Хасанова Д.Р., Фатеева В.В. Астенические и когнитивные нарушения у пациентов, перенесших COVID-19. РМЖ. Медицинское обозрение. 2021; 10: 636–641.

45. Parums D.V. Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care. Med Sci Monit. 2021; 27: e933446. https://dx.doi.org/10.12659/MSM.933446.

46. Duncan E., Cooper K., Cowie J. et al. A national survey of community rehabilitation service provision for people with long Covid in Scotland. F1000Res. 2021; 9: 1416. https://dx.doi.org/10.12688/f1000research.27894.2.

47. Орлов Ю.П., Афанасьев В.В., Хиленко И.А. Перспектива сукцинатов в условиях гипоксии при COVID-19. Антибиотики и химиотерапия. 2021; 1–2: 66–75.

48. Камчатнов П.Р., Абусуева Б.А., Евзельман М.А. с соавт. Течение острого ишемического инсульта у больных, получавших Цитофлавин. Современная медицина. 2020; 1: 157–159.

49. Кондрашова М.Н. Гормоноподобное действие янтарной кислоты. Вопросы биологической медицины и фармацевтической химии. 2002; 1: 7–11.

50. Оленская Т.Л. Инновационные методы реабилитации на амбулаторном и домашнем этапах у пациентов после пневмонии COVID-19. Медицинский совет. 2021; 4: 220–229.